Market open
AlloVir/$ALVR
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About AlloVir
AlloVir Inc is a late clinical-stage cell therapy company. The company focuses on developing innovative allogeneic T-cell therapies to combat viral diseases. Their proprietary VST therapy platform enables the creation of off-the-shelf VSTs, addressing the urgent medical need for treating patients with limited viral disease treatment options. With a singular focus on research, development, and commercialization, the company's platform targets 11 devastating viruses, with posoleucel being the lead candidate addressing six viruses. Operating within one segment, the company is dedicated to preventing and treating severe viral-associated diseases through off-the-shelf VST therapies.
Ticker
$ALVR
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
8
Website
AlloVir Metrics
BasicAdvanced
$112M
Market cap
-
P/E ratio
-$1.23
EPS
0.77
Beta
-
Dividend rate
Price and volume
Market cap
$112M
Beta
0.77
52-week high
$2.49
52-week low
$0.58
Average daily volume
277K
Financial strength
Current ratio
55.082
Quick ratio
54.984
Long term debt to equity
6.93
Total debt to equity
7.484
Management effectiveness
Return on assets (TTM)
-36.53%
Return on equity (TTM)
-80.33%
Valuation
Price to book
0.93
Price to tangible book (TTM)
0.93
Price to free cash flow (TTM)
-0.93
Growth
Earnings per share change (TTM)
-32.70%
3-year earnings per share growth (CAGR)
-15.93%
What the Analysts think about AlloVir
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for AlloVir stock.
AlloVir Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
AlloVir Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
AlloVir News
AllArticlesVideos
STOCKHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of AlloVir, Inc. – ALVR
GlobeNewsWire·2 hours ago
Shareholder Alert: Ademi LLP Investigates Whether AlloVir, Inc. Is Obtaining a Fair Price for Its Public Shareholders
Business Wire·4 hours ago
AlloVir and Kalaris Therapeutics Announce Agreement for Transformational Merger to Create Company Focused on Diseases of the Retina
GlobeNewsWire·8 hours ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for AlloVir stock?
AlloVir (ALVR) has a market cap of $112M as of November 08, 2024.
What is the P/E ratio for AlloVir stock?
The price to earnings (P/E) ratio for AlloVir (ALVR) stock is 0 as of November 08, 2024.
Does AlloVir stock pay dividends?
No, AlloVir (ALVR) stock does not pay dividends to its shareholders as of November 08, 2024.
When is the next AlloVir dividend payment date?
AlloVir (ALVR) stock does not pay dividends to its shareholders.
What is the beta indicator for AlloVir?
AlloVir (ALVR) has a beta rating of 0.77. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.